5 Best Healthcare Stocks Under $20 According to Michael Castor’s Sio Capital

3. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Castor’s Stake Value: $7.86 million

Percentage of Michael Castor’s 13F Portfolio: 1.95%

Number of Hedge Fund Holders: 12

Stock Price as of September 23: $18.49

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a clinical-stage biotech company that focuses on the development and commercialization of a late-stage therapies and medication for the treatment of various cholestatic liver diseases. Ranked third on the list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has a market capitalization of $564.24 million.

According to the recent 13F Filings, Michael Castor’s Sio Capital Management holds 454,892 shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), amounting to over $7.86 million in worth and accounting for 1.95% of the fund’s portfolio. By the end of the second quarter of 2021, 12 hedge funds out of the 873 tracked by Insider Monkey held stakes in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) worth roughly $180.4 million. This is compared to 11 hedge funds in the previous quarter with a total stake value of approximately $208 million.

On August 5, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings report for the second quarter of 2021, with reported earnings per share at -$1.45, missing market estimates by $0.37. The company also reported revenues of $11.0 million, surpassing estimated revenues by $9.16 million.

Out of the hedge funds being tracked by Insider Monkey’s database, Washington-based investment firm Frazier Healthcare Partners is a leading shareholder in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) with over 3.56 million shares worth more than $61.67 million.

On September 20, JPMorgan analyst Jessica Fye began coverage of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) with an Overweight rating and $30 price target.